Shopping Cart
Remove All
Your shopping cart is currently empty
SDU-071 is an orally active BRD4-p53 inhibitor, inhibiting the proliferation of MDA-MB-231 cells, blocking the interaction between BRD4 and the tumor suppressor p53, downregulating the expression of BRD4-targeted genes, thereby inhibiting cell proliferation, migration, and invasion, and inducing cell cycle arrest and apoptosis. SDU-071 is used for research on triple-negative breast cancer.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $65 | - | In Stock | |
| 5 mg | $157 | - | In Stock | |
| 10 mg | $237 | - | In Stock | |
| 25 mg | $397 | - | In Stock | |
| 50 mg | $598 | - | In Stock | |
| 100 mg | $848 | - | In Stock | |
| 200 mg | $1,130 | - | In Stock |
| Description | SDU-071 is an orally active BRD4-p53 inhibitor, inhibiting the proliferation of MDA-MB-231 cells, blocking the interaction between BRD4 and the tumor suppressor p53, downregulating the expression of BRD4-targeted genes, thereby inhibiting cell proliferation, migration, and invasion, and inducing cell cycle arrest and apoptosis. SDU-071 is used for research on triple-negative breast cancer. |
| In vitro | SDU-071 is a novel BRD4-p53 inhibitor. SDU-071 (10 μM, 24 h) inhibits the interaction of BRD4 with p53 tumor suppressor. [1] |
| In vivo | In an orthotopic mouse xenograft breast tumor model, SDU-071 (250 mg/kg, gavage, Once a day for 21 days) showed good antitumor activity. [1] |
| Synonyms | SDU071 |
| Molecular Weight | 435.52 |
| Formula | C28H25N3O2 |
| Cas No. | 3036109-10-8 |
| Smiles | COC(C=C1)=CC=C1NCC(C=C2NC3=CC=C(OC)C=C3)=NC4=C2C=CC5=C4C=CC=C5 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (183.69 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (9.18 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.